|Bid||0.0000 x 3200|
|Ask||0.0000 x 4000|
|Day's range||1.7900 - 1.8400|
|52-week range||1.6700 - 11.6100|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||N/A|
|Earnings date||21 Jun 2023 - 26 Jun 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||14 Oct 1999|
|1y target est||1.50|
PHILADELPHIA, May 23, 2023--Elixir, a pharmacy benefit management company owned by Rite Aid (NYSE: RAD), has announced details of the next release of its Laker Software technology platform. The upcoming enhancements include new automated workflows, a customer service tool and modernization of the user interface.
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
PHILADELPHIA, April 26, 2023--It’s no secret seasonal allergies are here. From runny noses and itchy eyes to tissues carried in all pockets and bags, spring has sprung and mother nature has brought the dreaded sneeze with her. To help its suffering shoppers, Rite Aid has spent the last few weeks dusting off last season’s sales data* and speaking with real allergy victims to once and for all ‘Ease the Sneeze.’
CVS Health, Walgreens BootsAlliance, Rite Aid and Amazon have been highlighted in this Industry Outlook article.
Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain on the strength of their digital pharmacies.
Rite Aid's (RAD) Q4 results gain from improvements in retail pharmacy and Elixir. However, lower revenues from COVID vaccines and testing, and store closures act as headwinds.
Rite Aid (RAD) delivered earnings and revenue surprises of -61.04% and 6.90%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
PHILADELPHIA, April 20, 2023--Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourteen-week fourth quarter and fifty-three-week fiscal year ended March 4, 2023.
Higher non-COVID prescriptions, strength in PBM and delivery service expansion are likely to have impacted Rite Aid's (RAD) Q4 performance amid sluggishness in Retail Pharmacy and Pharmacy Services.
All three major pharmacy chains, CVS Health (NYSE: CVS), Walgreens Boots Alliance (NASDAQ: WBA), and Rite Aid (NYSE: RAD), have seen their shares drop over the past 12 months and so far this year. In its guidance, the company said it expects 2023 EPS of $7.73 to $7.93.
Walgreens (WBA) delivered earnings and revenue surprises of 5.45% and 4.16%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
PHILADELPHIA, March 23, 2023--Rite Aid Corporation (NYSE: RAD) will release financial results for its Fiscal 2023 Fourth Quarter, which ended March 4, 2023, on Thursday, April 20, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com.
Despite drab demand and supply-chain headwinds, Rite Aid's (RAD) online strength, led by expanded delivery services, increased non-COVID prescriptions and cost-saving initiatives, are likely to aid.
Walgreens faces backlash over misperception of its intent to sell abortion pill in some states.
The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.
Rite Aid (RAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Among the biggest news out of hedge funds and company top brass, Disney is girding for a proxy battle against Nelson Peltz. Walt Disney (NYSE:DIS) on Wednesday afternoon said it opposed efforts by activist investor Nelson Peltz, of Trian Fund Management, to join the company’s board - setting the stage for a proxy battle - and simultaneously announced it had elected seven-year board veteran Mark Parker as Disney's chairman.
Rite Aid (RAD) is reeling under elevated expenses. Yet, online strength, led by expanded delivery services, increased non-COVID prescriptions, and cost-saving initiatives, are likely to aid.
PHILADELPHIA, January 09, 2023--Rite Aid Corporation (NYSE: RAD) ("Rite Aid" or the "Company") announced today that its Board of Directors has appointed Elizabeth ("Busy") Burr, a member of the Company’s Board, as interim CEO, effective immediately. Burr’s appointment follows Heyward Donigan’s departure from the Company as President and CEO, and as a member of the Board. Rite Aid has initiated a search to identify a permanent CEO and has retained a leading executive search firm.
Rite Aid's (RAD) Q3 results reflect the impacts of drab demand in flu immunizations and COVID-19 vaccines. Also, management updates its fiscal 2023 view.
Walgreens Boots Alliance (NASDAQ: WBA) had a lousy day on an generally prosperous Wednesday for stocks. The rival in question is Rite Aid, which unveiled its third quarter of fiscal 2023 results before market open. While the company notched modest beats on both the top and bottom lines, it lowered its non-GAAP (adjusted) earnings before taxes, depreciation, and amortization (EBITDA) guidance for the entirety of the fiscal year.
Yahoo Finance Live anchors discuss why Rite Aid stock is tanking on Wednesday afternoon.
At this time, I would like to welcome everyone to the Rite Aid Corporation third-quarter fiscal year 2023 earnings conference call. Heyward Donigan, president and chief executive officer; and Matt Schroeder, executive vice president and chief financial officer, will begin the call with prepared remarks.
Shares of pharmacy stock Rite Aid (NYSE: RAD) fell as much as 17.3% in morning trading on Wednesday after reporting fiscal third-quarter 2023 financial results. Quarterly revenue fell 2.3% to $6.08 billion, and net loss nearly doubled to $67.1 million, or $1.23 per share. Management now expects full fiscal-year 2023 revenue to be between $23.7 billion and $24 billion, with a net loss of $584 million to $551 million.
Yahoo Finance Live anchors discuss third-quarter earnings for Rite Aid.